|Bid||3.2400 x 3200|
|Ask||3.7000 x 3200|
|Day's Range||3.1800 - 3.3100|
|52 Week Range||3.0200 - 6.3000|
|Beta (3Y Monthly)||2.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.75|
PLYMOUTH MEETING, Pa. and OSLO, Norway, May 21, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO), together with CEPI, today announced it has dosed subjects in a Phase 1, first-in-human clinical trial to evaluate INO-4500, its DNA candidate vaccine to prevent infection from the Lassa virus. Inovio plans to enroll approximately 60 volunteers in this placebo controlled, blinded, dose escalation study evaluating INO-4500 for safety, tolerability and immune responses. This Inovio trial represents the first Lassa candidate vaccine to enter the clinic.
QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to respond to VGX-3100, Inovio's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus virus (HPV). This precision medicine partnership focuses on Inovio's VGX-3100, a late-stage product candidate currently in two pivotal Phase 3 clinical trials (REVEAL 1 and 2) with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, May 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals Inc. (INO) and Plumbline Life Sciences (XKRX:222670) today announced a collaboration to co-develop a novel animal health vaccine for African swine fever (ASF) virus. The vaccine will be developed using Inovio's SynCon® technology and delivered using CELLECTRA® efficacy-enabling devices. Plumbline, based in South Korea, will fund all development and commercialization of the ASF vaccine.
Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.
More revenue, more cash, lower expenses, and a lot of pipeline activity were the major stories for the biotech in Q1.
Inovio (INO) delivered earnings and revenue surprises of -3.45% and -36.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Plymouth Meeting, Pennsylvania-based company said it had a loss of 30 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
PLYMOUTH MEETING, Pa. , May 9, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development and commercialization of its synthetic ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.
PLYMOUTH MEETING, Pa. , May 6, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that its lead Phase 3 product candidate, VGX-3100, has been granted an Advanced Therapy Medicinal ...
Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.
Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLYMOUTH MEETING, Pa., May 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that first quarter 2019 financial results will be released after the market close on May 9, 2019. Following the release, the Company will host a conference call and live webcast at 4:30 p.m. ET, to provide a general business update and financial results for the first quarter 2019. Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines that transform the treatment and prevention of cancer and infectious disease. Inovio's proprietary technology platform applies antigen sequencing and DNA delivery to activate potent immune responses to targeted diseases. The technology functions exclusively in vivo, and has been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens.
While many biopharmaceutical companies have partnerships or collaborations with one or two larger companies, Inovio Pharmaceuticals has product development deals in place with more than a half dozen pharmaceutical and biotech firms and research organizations inside and outside the United States. Inovio is in that position largely because it is developing a technology platform with two parts that can be applied to a variety of medical conditions. The second part is the system for delivering the therapy through the skin or into muscle tissues using brief and low voltage electronic pulses. That standing, said Inovio co-founder and CEO J. Joseph Kim, gives the Plymouth Meeting-based company different aspirations than other development-stage drug developers.